Baker Bros. Advisors LP bought $24M of IMCR
director at Immunocore Holdings plc. 807,338 shares at an average of $29.72, traded Mar 17, 2025, filed Mar 19, 2025.
Score components
- +15RoleDirector
- +25Trade size$24.0M at market
- +10Relative to holdingsHoldings up 735%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-042242, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2025 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +60,110 | $29.74 | $1.8M | 170,007 | Mar 19, 2025 |
| Mar 17, 2025 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +646,290 | $29.74 | $19M | 2,051,711 | Mar 19, 2025 |
| Mar 17, 2025 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +8,589 | $29.56 | $254k | 178,596 | Mar 19, 2025 |
| Mar 17, 2025 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +92,349 | $29.56 | $2.7M | 2,144,060 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale 2.5% Convertible Senior Notes due 2030derivativeindirect: See Footnotes | - | $10,533,376.12 | - | 0 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale 2.5% Convertible Senior Notes due 2030derivativeindirect: See Footnotes | - | $113,252,773.88 | - | 0 | Mar 19, 2025 |
Related signals
Other insiders at Immunocore Holdings plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | Immunocore Holdings plc | David M Berman HEAD OF R&D | $193k 5,965 shares | -50% | |
| 35Weak | Immunocore Holdings plc | John Goll SVP, FINANCE & CAO | $23k 698 shares | -52% | |
| 50Moderate | Immunocore Holdings plc | Bahija Jallal CHIEF EXECUTIVE OFFICER | $371k 11,474 shares | -48% | |
| 30Weak | Immunocore Holdings plc | Tina Amber St Leger CHIEF HR OFFICER | $32k 1,000 shares | -47% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $1.3M 31,913 shares | -102% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $3.0M 74,925 shares | -108% | |
| 21Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $725k 18,120 shares | -18120% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $2.2M 61,849 shares | -100% | |
| 22Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $811k 22,732 shares | -101% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $1.8M 50,419 shares | -161% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.